Using Driver Control Models to Understand and Evaluate Behavioral Validity of Driving Simulators

For a driving simulator to be a valid tool for research, vehicle development, or driver training, it is crucial that it elicits similar driver behavior as the corresponding real vehicle. To assess such behavioral validity, the use of quantitative driver models has been suggested but not previously reported. Here, a task-general conceptual driver model is proposed, along with a taxonomy defining levels of behavioral validity. Based on these theoretical concepts, it is argued that driver models without explicit representations of sensory or neuromuscular dynamics should be sufficient for a model-based assessment of driving simulators in most contexts. As a task-specific example, two parsimonious driver steering models of this nature are developed and tested on a dataset of real and simulated driving in near-limit, low-friction circumstances, indicating a clear preference of one model over the other. By means of closed-loop simulations, it is demonstrated that the parameters of this preferred model can generally be accurately estimated from unperturbed driver steering data, using a simple, open-loop fitting method, as long as the vehicle positioning data are reliable. Some recurring patterns between the two studied tasks are noted in how the model’s parameters, fitted to human steering, are affected by the presence or absence of steering torques and motion cues in the simulator

Understanding Cue Utility in Controlled Evasive Driving Manoeuvres: Optimizing Vestibular Cues for Simulator & Human Abilities

Most daily driving tasks are of low bandwidth and therefore the relatively slow visual system receives enough cue information to perform the task in a manner that is statistically indistinguishable from reality. On the other hand, evasive maneuvers are of such a high bandwidth that waiting for the visual cues to change is too slow and skilled drivers use steering torques and vestibular motion cues to know how the car is responding in order to make rapid corrective actions. In this study we show for evasive maneuvers on snow and ice, for which we have real world data from skilled test drivers, that the choice of motion cuing algorithm (MCA) settings has a tremendous impact on the saliency of motion cues and their similarity with reality. We demonstrate this by introducing a novel optimization scheme to optimize the classic MCA in the context of an MCA-Simulator-Driver triplet of constraints. We incorporate the following four elements to tune the MCA for a particular maneuver: 1) acceleration profiles of the maneuver observed in reality, 2) vestibular motion perception model, 3) motion envelope constraints of the simulator, and 4) a set of heuristics extracted from the literature about human motion perception (i.e. coherence zones). Including these elements in the tuning process, notwithstanding the easiness of the tuning process, respects motion platform constraints and considers human perception. Moreover the inevitable phase and gain errors arising as a major consequence of MCA are always kept within the human coherence zones, and subsequently are not perceptible as false cues. It is expected that this approach to MCA tuning will increase the transfer of training from simulator to reality for evasive driving maneuvers where students need training most and are most dangerous to perform in reality

Where is SUSY?

The direct searches for Superymmetry at colliders can be complemented by direct searches for dark matter (DM) in underground experiments, if one assumes the Lightest Supersymmetric Particle (LSP) provides the dark matter of the universe. It will be shown that within the Constrained minimal Supersymmetric Model (CMSSM) the direct searches for DM are complementary to direct LHC searches for SUSY and Higgs particles using analytical formulae. A combined excluded region from LHC, WMAP and XENON100 will be provided, showing that within the CMSSM gluinos below 1 TeV and LSP masses below 160 GeV are excluded (m_{1/2} > 400 GeV) independent of the squark masses.Comment: 16 pages, 10 figure

6-thioguanine treatment in inflammatory bowel disease: A critical appraisal by a European 6-TG working party

Recently, the suggestion to use 6-thioguanine (6-TG) as an alternative thiopurine in patients with inflammatory bowel disease (IBD) has been discarded due to reports about possible (hepato) toxicity. During meetings arranged in Vienna and Prague in 2004, European experts applying 6-TG further on in IBD patients presented data on safety and efficacy of 6-TG. After thorough evaluation of its risk-benefit ratio, the group consented that 6-TG may still be considered as a rescue drug in stringently defined indications in IBD, albeit restricted to a clinical research setting. As a potential indication for administering 6-TG, we delineated the requirement for maintenance therapy as well as intolerance and/or resistance to aminosalicylates, azathioprine, 6-mercaptopurine, methotrexate and infliximab. Furthermore, indications are preferred in which surgery is thought to be inappropriate. The standard 6-TG dosage should not exceed 25 mg daily. Routine laboratory controls are mandatory in short intervals. Liver biopsies should be performed after 6-12 months, three years and then three-yearly accompanied by gastroduodenoscopy, to monitor for potential hepatotoxicity, including nodular regenerative hyperplasia (NRH) and veno-occlusive disease (VOD). Treatment with 6-TG must be discontinued in case of overt or histologically proven hepatotoxicity. Copyright (c) 2006 S. Karger AG, Basel

Future of Pharmacogenetics in Cardiovascular Diseases

Introduction: Pharmacogenetics is the study of variations in DNA sequence as related to drug response (European Medicines Agency [EMA], 2007). Several gene-drug interactions have been discovered in the field of cardiovascular diseases (CVDs). These gene-drug interactions can help to identify nonresponse to drugs, estimate dose requirements or identify an increased risk of developing adverse drug reactions. An individualized approach based on pharmacogenetic testing will provide physicians and pharmacists with tools for decision making about pharmacotherapy. While pharmacogenetic testing is already part of everyday practice in oncology, it is not widely implemented in the field of CVDs. However, in the near future, pharmacogenetics will probably also play a valuable role in this field as well

Economic evaluation of a pharmacogenetic dosing algorithm for coumarin anticoagulants in The Netherlands

Aims: to investigate the cost-effectiveness of a pharmacogenetic dosing algorithm versus a clinical dosing algorithm for coumarin anticoagulants in The Netherlands. Materials & methods: A decision-analytic Markov model was used to analyze the cost-effectiveness of pharmacogenetic dosing of phenprocoumon and acenocoumarol versus clinical dosing. Results: Pharmacogenetic dosing increased costs by €33 and QALYs by 0.001. The incremental cost-effectiveness ratios (ICERs) were €28,349 and €24,427 per QALY gained for phenprocoumon and acenocoumarol respectively. At a willingness to pay threshold of €20,000 per QALY, the pharmacogenetic dosing algorithm was not likely to be cost-effective compared to the clinical dosing algorithm. Conclusions: Pharmacogenetic dosing improves health only slightly when compared with clinical dosing. However, availability of low-cost genotyping would make it a cost-effective option